No broadly approved vaccine for urinary tract infections exists yet, but several candidates have reached human clinical trials and produced encouraging results. The closest to widespread clinical use is MV140, a sublingual preparation that dramatically cut recurrence rates in a randomized controlled trial published in 2024. Behind it, a pipeline of conjugate, adhesin-based, and even mRNA-platform vaccines are working through earlier trial phases, driven largely by the reality that recurrent UTIs are still managed mainly with long-term antibiotics, and antibiotic resistance is making that approach increasingly fragile.
Why the Push for a UTI Vaccine Has Intensified
Urinary tract infections are among the most common bacterial infections worldwide, and recurrence is the central problem. Roughly a quarter to a third of women who get one UTI will have another within six months. The standard response has been repeated or even continuous courses of antibiotics, but resistance to first-line drugs like trimethoprim-sulfamethoxazole and fluoroquinolones has climbed steadily. The rise in antibiotic resistance has complicated the management of chronic UTIs and pushed researchers toward preventive strategies that do not rely on killing bacteria with drugs.1PubMed Central. Siderophore vaccine conjugates protect against uropathogenic Escherichia coli urinary tract infection Long-term antibiotic use for recurrent UTIs itself contributes to the problem, making vaccine development feel more urgent than ever.2PubMed Central. A sublingual nanofiber vaccine to prevent urinary tract infections
Developing a UTI vaccine is harder than it sounds. Most UTIs are caused by uropathogenic strains of E. coli, but those strains are genetically diverse and use a range of tricks to invade and persist. Researchers have identified targets across several categories of virulence, including immune evasion via capsule formation, iron acquisition systems, adhesion molecules, and toxins.3PubMed Central. Comparative Pathogenomics of Escherichia coli: Polyvalent Vaccine Target Identification through Virulome Analysis A vaccine that blocks just one of those strategies might be sidestepped by strains that rely on a different one. That complexity has spawned several parallel approaches, each targeting a different piece of the puzzle.
MV140, the Sublingual Vaccine With the Strongest Human Data
The candidate farthest along the clinical road is MV140, a sublingual vaccine made from inactivated whole bacteria. You spray it under the tongue daily for three or six months. It is already approved and in clinical use in Spain under the name Uromune, and it has been the subject of observational studies in Europe for several years. What changed the conversation was a double-blind, randomized, placebo-controlled trial whose results were published in NEJM Evidence in 2024.
In that trial, women with a history of recurrent UTIs were randomly assigned to placebo, three months of MV140, or six months of MV140. The results were striking. Women on placebo had a median of three UTI episodes during the follow-up period. Women who received either duration of MV140 had a median of zero. Roughly a quarter of the placebo group stayed UTI-free, compared with about 56 to 58 percent of the women on MV140. The side-effect profile was mild, and the MV140 groups actually reported fewer adverse events overall than the placebo group.4PubMed. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections
A separate North American study reported a UTI-free rate of about 41 percent during a nine-month follow-up and a roughly 75 percent reduction in infection rate compared to the year before vaccination.5PubMed Central. MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study Across both observational and controlled studies, MV140 has been shown to reduce antibiotic use, lower healthcare costs, and improve quality of life in women with recurrent UTIs.6PubMed Central. An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women
The sublingual route is part of what makes MV140 distinctive. Most traditional vaccines are injected, but mucosal immunization through the mouth can generate immune responses in the urogenital tract, which is exactly where you want defenses against UTI pathogens. This approach avoids needles entirely and can be self-administered at home, which matters for a condition requiring long treatment courses.
Bacterial Lysate Products Already in Use in Some Countries
MV140 is not the only immunotherapy that has reached patients. Two bacterial lysate products, Uro-Vaxom and StroVac, have been available in parts of Europe for years, though neither has gained approval in the United States or Canada.
Uro-Vaxom is an oral capsule containing extracts of 18 strains of E. coli. It works by stimulating the immune system broadly rather than targeting a single protein. A systematic review summarizing multiple trials found consistently positive results. In one study, about 67 percent of Uro-Vaxom-treated patients stayed recurrence-free versus 22 percent on placebo. Another found average UTI episodes dropped from about four in the six months before treatment to 0.35 in the six months after. A third documented a 34 percent relative reduction in UTI relapse rates compared to placebo. Long-term protection persisted even after patients stopped taking the capsules.7PubMed Central. Efficacy and Safety of Uro-Vaxom in Urinary Tract Infection Prevention: A Systematic Literature Review
StroVac takes a different delivery route. It is a parenteral (injected) vaccine containing inactivated strains of several uropathogens, not just E. coli. A comparative study pitted StroVac against nitrofurantoin, a standard antibiotic used for UTI prevention. In the first year, both approaches worked about equally well, with around 87 to 92 percent of women staying infection-free. But in the second year, StroVac pulled ahead: roughly 79 percent of vaccinated women remained UTI-free compared with only about 59 percent on the antibiotic. Critically, side effects were far less common with StroVac. Only about 2 percent of vaccinated patients dropped out due to adverse reactions, versus 18 percent who stopped nitrofurantoin, mostly because of gastrointestinal complaints.8PubMed. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study
These lysate products are sometimes categorized as “immunostimulants” rather than vaccines in a traditional sense, because they do not target a single defined antigen. That distinction matters more to regulators than to patients. From a practical standpoint, they are preventive treatments that train the immune system to fight off UTI-causing bacteria, and the evidence for their efficacy is substantial enough that European urology guidelines already include them as options.
ExPEC4V, the Conjugate Vaccine Targeting Surface Sugars
A fundamentally different strategy is behind ExPEC4V, a vaccine that targets the sugar molecules (O-antigens) on the surface of the four E. coli serotypes most commonly responsible for UTIs and other invasive infections. The four serotypes included, O1A, O2, O6A, and O25B, were chosen based on epidemiological surveys of UTI-causing strains in Switzerland, Germany, and the United States.9PubMed. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli
In a first-in-human phase 1b trial, 93 women with recurrent UTIs received ExPEC4V and 95 received placebo. The vaccine was well tolerated, with no serious vaccine-related adverse events. It triggered strong antibody responses against all four serotypes. Antibody levels were several-fold higher than baseline within a month and persisted, though at lower levels, out to 270 days. The trial was not designed or powered to detect a clear reduction in UTIs caused specifically by the four vaccine serotypes, and indeed it did not find one. However, it did find a significant drop in UTIs caused by E. coli of any serotype, which was an unexpected bonus suggesting some broader protective effect.10The Lancet Infectious Diseases. Safety and immunogenicity of a tetravalent E coli O-antigen bioconjugate vaccine in healthy adults: a randomised, placebo-controlled, phase 1b trial
A subsequent phase 2 study confirmed that ExPEC4V elicited strong, functional immune responses across all four serotypes, with at least 82 percent of vaccinated participants showing at least a twofold increase in antibody levels by day 15.11Open Forum Infectious Diseases. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants Phase 2 efficacy trials have been initiated, but ExPEC4V still has a longer regulatory road ahead compared to MV140.
FimH Adhesin Vaccines and the mRNA Frontier
If O-antigen vaccines target what the bacterium looks like on the outside, FimH vaccines target what the bacterium does. FimH is the protein at the tip of tiny hair-like structures called type 1 pili that most UTI-causing E. coli use to latch onto the bladder wall. Block that attachment and the bacteria get flushed out with urine before they can establish an infection.
A first-in-human phase 1 trial of an adjuvanted FimH vaccine showed it was safe and triggered both binding and functional antibodies in women with and without UTI histories.12PubMed Central. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study Researchers also developed a lab assay to verify that the antibodies generated were genuinely functional, meaning they could block FimH from binding to its target.13PubMed Central. Optimization and qualification of an assay that demonstrates that a FimH vaccine induces functional antibody responses in women with histories of urinary tract infections The interest in FimH is not limited to vaccine developers. A randomized clinical trial of d-mannose, a sugar supplement sometimes taken for UTI prevention, noted that synthetic mannosides and a FimH vaccine both work on the same principle of blocking pilus binding.14JAMA Network. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial
One intriguing wrinkle is that FimH also helps E. coli colonize the gut, which serves as a reservoir from which bacteria can migrate to the urinary tract. A recent mouse study found that a mucosal FimH vaccine could reduce gut colonization by UTI-causing E. coli, but the effect depended on how well established the bacteria already were. If the bacteria had deeply occupied their gut niche before vaccination, the vaccine was less effective at dislodging them.15PubMed Central. Uropathogenic Escherichia coli niche occupancy determines the effects of mucosal vaccine against FimH That finding raises practical questions about timing: vaccination might work best before a person becomes heavily colonized.
The newest twist is the application of mRNA vaccine technology, familiar from COVID-19 vaccines, to the UTI problem. Researchers have developed a lipid nanoparticle mRNA vaccine encoding a FimH-ferritin fusion protein. In mouse and rat models, it generated functional antibodies against both homologous and heterologous (genetically different) UTI-causing E. coli strains, and significantly reduced bladder bacterial load in a recurrent UTI model. It produced stronger functional antibody levels than protein-based vaccine comparators.16Frontiers in Immunology. An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli confers protection in a mouse model of recurrent urinary tract infection This is still animal-stage research, but it suggests the mRNA platform could accelerate UTI vaccine development the same way it did for other infectious diseases.
Beyond the Standard Patient Profile
Most vaccine trials have focused on otherwise healthy adult women with recurrent uncomplicated UTIs, but the need extends well beyond that population. Catheter-associated UTIs are a major source of hospital-acquired infections, and they are caused by different organisms and mechanisms. Researchers at Washington University have explored a vaccine targeting EbpA, a protein used by Enterococcus faecalis to form biofilms on catheters. In mouse models, vaccination with EbpA inhibited biofilm formation and protected against catheter-associated UTIs.17Washington University in St. Louis Technology Licensing. Vaccine to prevent catheter-associated urinary tract infection This work is still preclinical, but it highlights that any complete UTI vaccine strategy will probably need multiple products aimed at different settings.
Children are another population where UTI prevention matters enormously, especially those with structural abnormalities like vesicoureteral reflux, where urine flows backward from the bladder toward the kidneys. A systematic review of UTI vaccines in children noted that vaccines may provide less benefit in this group if anatomical issues are not surgically corrected, since the structural problem predisposes to infection regardless of immune status.18Journal of Pediatric Surgery Open. Vaccines for urinary tract infections in children: A systematic review For children without such structural issues, immunotherapy could theoretically reduce the cycle of recurrent infections and repeated antibiotic courses that can disrupt their developing microbiome, but pediatric-specific trial data remains thin.
The Economics of Preventing Rather Than Treating
Cost is always part of the conversation when new preventive therapies enter the picture, and the early economic analyses favor vaccination. A study of MV140 found that the direct annual healthcare cost per patient with recurrent UTIs dropped from about €1,001 before vaccination to roughly €497 afterward. Even after adding in the cost of the vaccine itself (about €172 per treatment course), total UTI-related expenses per patient per year still fell significantly, to around €669.19PubMed Central. Cost-Effectiveness of a Sublingual Bacterial Vaccine for the Prophylaxis of Recurrent Urinary Tract Infections
A separate cost-utility analysis compared MV140 directly against prophylactic antibiotics. MV140 was associated with cost savings of about $1,442 per patient and a small improvement in quality-adjusted life years. It dominated prophylactic antibiotics in the base case and in most alternative scenarios tested.20PubMed Central. The sublingual vaccine MV140 is dominant over prophylactic antibiotics for the prevention of recurrent, uncomplicated urinary tract infections in adult women A cost-utility analysis Those savings come from fewer doctor visits, fewer courses of antibiotics, fewer urine cultures, and fewer emergency department trips. For healthcare systems dealing with millions of recurrent UTI cases per year, those numbers add up quickly.
How Your Immune System Naturally Learns From UTIs
One reason vaccine development took so long to gain traction is that for decades, scientists assumed the bladder’s immune system did not develop lasting memory against UTI pathogens. Recent research challenges that assumption. A study on innate immune cells in the bladder, specifically a type called group 3 innate lymphoid cells, found that after a first UTI, these cells develop what researchers call “trained immunity.” Upon a second infection, the trained cells proliferate faster, produce more of the signaling molecules that recruit other defenses, and improve clearance of the invading bacteria. They also reinforce the physical barrier of the bladder lining by boosting production of natural antimicrobial compounds.21PubMed. Trained Immunity in Bladder ILC3s Enhances Mucosal Defense Against Recurrent Urinary Tract Infections The discovery that the bladder can, in fact, build memory-like immune responses is exactly the kind of finding that validates the vaccine approach. If the immune system is capable of learning to fight off UTI-causing bacteria more effectively, a vaccine just gives it a safer and more controlled lesson.
This also helps explain why some vaccine approaches focus on mucosal delivery rather than traditional injection. Getting immune cells in and around the urogenital tract to respond is arguably more relevant to UTI prevention than generating high antibody levels in the bloodstream. That logic underlies the sublingual route used by MV140 and the mucosal FimH vaccines in preclinical development.
Where Things Stand for People Living With Recurrent UTIs
If you are dealing with recurrent UTIs right now, your access to these vaccines depends almost entirely on where you live. MV140 is available in Spain and has been used off-label or through special access programs in parts of Europe, Canada, and a handful of other countries. Uro-Vaxom and StroVac are available in various European and some Asian markets. None of these products are approved by the FDA in the United States. The FimH and ExPEC4V vaccines remain in clinical trials and are not available outside of study enrollment.
For people in countries where none of these are accessible, the practical landscape has not changed as dramatically as the research landscape. Antibiotic prophylaxis, behavioral modifications like post-intercourse voiding, and topical estrogen for postmenopausal women remain the main evidence-based options. Some people use cranberry products or d-mannose supplements, though the evidence for those is more mixed. But the pipeline is real, the trial results are strong, and the economic case for prevention over treatment keeps building. The question is no longer whether a UTI vaccine can work, but when and where it will become routinely available.